Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in MODY
NCT07029009Phase 2Recruiting
- Sponsor
- Mansa Bioworks
- Start
- May 2025
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liraglutide in Maturity Onset Diabetes of the Young (MODY), sponsored by Mansa Bioworks. Primary endpoints: Hemoglobin A1c at 3 months and Body Mass Index at 3 months. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
Maturity Onset Diabetes of the Young (MODY)
Beyond the preview
Go deeper on NCT07029009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029009.